Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -28.20% is 45% above its 5-year average of -50.97%, near the high end of its 5-year range (-84.18%–-13.04%).
As of the fiscal period ended Tuesday, June 30, 2026. 45.81% above its 12-month average of -52.04%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -28.20%.
RETURN ON EQUITY (ROE)
-28.20%
RETURN ON EQUITY (ROE) AVG TTM
-52.04%
RETURN ON EQUITY (ROE) AVG 3Y
-56.74%
RETURN ON EQUITY (ROE) AVG 5Y
-50.97%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+45.81%
CURRENT VS 3Y AVG
+50.30%
CURRENT VS 5Y AVG
+44.68%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+32.87%
vs the sector median at left
Instil Bio, Inc.
Market Cap
$46.76M
Return on Equity (ROE)
-28.20%
TTM Avg
-52.04%
3Y Avg
-56.74%
5Y Avg
-50.97%
Market Cap
$46.31M
Return on Equity (ROE)
N/A
TTM Avg
-206.96%
3Y Avg
-221.50%
5Y Avg
-349.91%
Market Cap
$47.81M
Return on Equity (ROE)
-170.94%
TTM Avg
-132.56%
3Y Avg
-85.15%
5Y Avg
-88.00%
Market Cap
$45.03M
Return on Equity (ROE)
-212.45%
TTM Avg
-170.64%
3Y Avg
-104.70%
5Y Avg
-78.05%
Market Cap
$44.76M
Return on Equity (ROE)
513.56%
TTM Avg
488.17%
3Y Avg
265.30%
5Y Avg
226.12%
Market Cap
$45.05M
Return on Equity (ROE)
123.04%
TTM Avg
-60.38%
3Y Avg
-75.18%
5Y Avg
-82.51%
Market Cap
$49.21M
Return on Equity (ROE)
N/A
TTM Avg
-374.04%
3Y Avg
-326.22%
5Y Avg
-254.86%
Market Cap
$49.44M
Return on Equity (ROE)
-23.70%
TTM Avg
-170.56%
3Y Avg
-190.10%
5Y Avg
-146.13%
Market Cap
$49.47M
Return on Equity (ROE)
-17.84%
TTM Avg
-32.49%
3Y Avg
-23.88%
5Y Avg
-18.14%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Instil Bio, Inc. (TIL) | $46.76M | -28.20% | -52.04% | -56.74% | -50.97% |
| Celularity Inc. (CELU)vs › | $46.31M | N/A | -206.96% | -221.50% | -349.91% |
| Lite Strategy, Inc. (LITS)vs › | $47.81M | -170.94% | -132.56% | -85.15% | -88.00% |
| Werewolf Therapeutics, Inc. (HOWL)vs › | $45.03M | -212.45% | -170.64% | -104.70% | -78.05% |
| SANUWAVE Health Inc. (SNWV)vs › | $44.76M | 513.56% | 488.17% | 265.30% | 226.12% |
| DarioHealth Corp. (DRIO)vs › | $45.05M | 123.04% | -60.38% | -75.18% | -82.51% |
| TELA Bio, Inc. (TELA)vs › | $49.21M | N/A | -374.04% | -326.22% | -254.86% |
| Microbot Medical Inc. (MBOT)vs › | $49.44M | -23.70% | -170.56% | -190.10% | -146.13% |
| Precision Optics Corporation, Inc. (POCI)vs › | $49.47M | -17.84% | -32.49% | -23.88% | -18.14% |
| Sensus Healthcare, Inc. (SRTS)vs › | $49.06M | -42.01% | -2.07% | 11.82% | 5.22% |
ROE
-28.2%
ROA
-15.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -28.20% |
| 2026-03-31 | -42.80% |
| 2025-12-31 | -62.68% |
| 2025-09-30 | -62.34% |
| 2025-06-30 | -64.18% |
| 2025-03-31 | -53.85% |
| 2024-12-31 | -43.75% |
| 2024-09-30 | -42.63% |
| 2024-06-30 | -61.32% |
| 2024-03-31 | -59.91% |
| 2023-12-31 | -69.12% |
| 2023-09-30 | -84.18% |
| 2023-06-30 | -62.66% |
| 2023-03-31 | -72.67% |
| 2022-12-31 | -61.38% |
| 2022-09-30 | -54.72% |
| 2022-06-30 | -46.14% |
| 2022-03-31 | -36.92% |
| 2021-12-31 | -28.24% |
| 2021-09-30 | -19.72% |
| 2021-06-30 | -13.04% |
| 2021-03-31 | -8.54% |
| 2020-12-31 | -12.91% |
